Skip to main content

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Trial Status: Active

The purpose of this study is to determine whether nivolumab in combination with relatlimab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread

Inclusion Criteria

  • Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system
  • Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma
  • Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses

Exclusion Criteria

  • Participants must not have active brain metastases or leptomeningeal metastases
  • Participants must not have uveal melanoma
  • Participants must not have an active, known, or suspected autoimmune disease

Arizona

Tucson
Banner University Medical Center - Tucson
Status: CLOSED_TO_ACCRUAL

California

Los Angeles
Translational Oncology Research International
Status: ACTIVE
UCLA / Jonsson Comprehensive Cancer Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Kyanne O'Bryant
Phone: 310-794-6500

District of Columbia

Washington
MedStar Georgetown University Hospital
Status: ACTIVE

Florida

Jacksonville
Mayo Clinic in Florida
Status: ACTIVE
Tampa
Moffitt Cancer Center
Status: ACTIVE
Contact: Zeynep Eroglu
Phone: 800-456-7121

Illinois

Chicago
Northwestern University
Status: ACTIVE

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE
MedStar Franklin Square Medical Center / Weinberg Cancer Institute
Status: ACTIVE

Massachusetts

Boston
Beth Israel Deaconess Medical Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE
Contact: Stephen Hodi

Michigan

Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: ACTIVE

Minnesota

Rochester
Mayo Clinic in Rochester
Status: ACTIVE

Texas

Houston
M D Anderson Cancer Center
Status: ACTIVE

Trial Phase Phase II/III

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

  • Primary ID CA224-047
  • Secondary IDs NCI-2018-01005, 2017-003583-12
  • Clinicaltrials.gov ID NCT03470922